Assertion Contradicted AI assessment confidence: 95% certainty 4/5 debate potential 3/5

Pande: FDA rejects new drugs that are cheaper but equal in efficacy

Vijay Pande · Tony Robbins on the Future of Health & Longevity · Dec 20, 2023 · at 13:03

Dr. Vijay Pande, General Partner at a16z, argues that insurance payers rather than the FDA should evaluate the economic value and efficacy of new drugs.

0:00 / 0:13exact quote · 14.0s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“If you had a drug that was as good as the best drug, but cheaper, That still can't get that won't go by the FDA because they actually has to be better than the last drug, even if it's not better scientifically, but it's better in other ways.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Dr. Vijay Pande claims the FDA will not approve a drug that is cheaper but only equal in efficacy to existing drugs, because the agency requires a new drug to be scientifically superior.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

The claim is false. Under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA requires a sponsor to demonstrate safety and 'substantial evidence' of effectiveness for a drug's intended use, but does not require demonstration of scientific or clinical superiority over existing approved drugs. Furthermore, FDA regulatory guidance explicitly permits active-controlled non-inferiority trials to establish effectiveness, and the FDA has no statutory authority to evaluate or consider drug pricing during the approval process.

Section 505 of the FD&C Act (21 U.S.C. § 355) standard for NDA approval requires substantial evidence of safety and efficacy, with no requirement for superiority over existing treatments.
FDA Industry Guidance on Non-Inferiority Clinical Trials confirms that demonstrating non-inferior (equivalent) efficacy satisfies statutory approval standards.
By statute, the FDA does not regulate, evaluate, or consider drug pricing or cost-effectiveness when making drug approval decisions.

Checked against

[1] arnoldporter.com [2] scientist.com [3] nih.gov [4] fda.gov [5] akronbiotech.com [6] agg.com [7] fda.gov [8] tedgiovanis.com

Does FDA require drug superiority over existing treatments FDA drug approval requirements non inferiority superiority FD C Act FD C Act section 505 substantial evidence efficacy superiority FDA drug approval standard superiority statutory requirement does FDA consider drug cost in approval process FDA guidance non inferiority clinical trials drug approval

assessed as of 2026-07-31

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

drugs FDA

⚑ Spot an error? Report it

More from Vijay Pande

Prediction Not checkable as stated

Pande: Cancer could easily not exist in 10 years

“Cancer could easily just not exist in 10 years, and that's due to this change in how we think about things, and there's all these things on the back end.”

Vijay Pande Jul 15, 2017 ▶ 12:46 On Machine Learning in Medicine and More

Prediction Not checkable as stated

Vijay Pande: Compute costs will fall a million-fold over 20 years

“The nice thing about the exponentials is that, you know, things will go down a factor of a thousand, like, every 10 years on the Moore's Law side, and we'll continue to see that. So, a thousand, maybe in 20 years, a million, you know, a thousand times a thousa…”

Vijay Pande Sep 5, 2024 ▶ 9:59 Implementation, Data, Impact of Healthcare AI with Julie and Vijay

Insight

Pande: Healthcare AI needs a 10x improvement threshold to overcome stigma

“Yeah, so I think the bar is different. This might be the magic has to get to 10 X. Mm-hmm. Something where 10% is probably within noise and without doubt or something like that, but 10 X is kind of the thing where, like, okay, okay. We have to think of things …”

Vijay Pande Sep 5, 2024 ▶ 19:49 Implementation, Data, Impact of Healthcare AI with Julie and Vijay

Prediction Not checkable as stated

Pande: Healthcare service providers will eventually transition into AI companies

“Well, you can imagine a services company that's providing some sort of healthcare service. It's training AI with its workers. And then the easy things, which are probably the boring things anyways, AI starts to do. And then the more interesting, complicated th…”

Vijay Pande Sep 5, 2024 ▶ 22:36 Implementation, Data, Impact of Healthcare AI with Julie and Vijay

Prediction Open · timeframe Jan 2028

Pande: The world's largest company will be in consumer health tech

“The biggest company in the world will be a consumer health tech company.”

Vijay Pande Jan 27, 2023 ▶ 46:42 2023 Big Ideas in Technology (Part 2)

Assertion Not checkable as stated

Pande: AI is turning scientific discovery into an industrialized process

“Today, what I want to talk about is how AI is industrializing discovery.”

Vijay Pande Nov 21, 2019 ▶ 0:21 AI is Industrializing Discovery

Pande: FDA rejects new drugs that are cheaper but equal in efficacy

More from Vijay Pande

Turn any episode into a week of clips.